帕博西利布
乳腺癌
医学
细胞周期蛋白依赖激酶
癌症
临床试验
肿瘤科
细胞周期蛋白依赖激酶4
疾病
内科学
转移性乳腺癌
细胞周期
细胞周期蛋白依赖激酶2
作者
Dimitrios Zardavas,Noam Falbel Ponde,Konstantinos Tryfonidis
标识
DOI:10.1080/13543784.2017.1389896
摘要
INTRODUCTION: Dysregulated cellular proliferation, one of the hallmarks of cancer, is mediated by aberrant activation of the cell cycle machinery through the biological effects of cyclin-dependent kinases (CDKs). The clinical development of non-selective CDK inhibitors failed due to combined lack of efficacy and excessive toxicity reported by clinical trials across different cancer types. The clinical development of second generation, CDK4/6-selective inhibitors, namely palbociclib, abemaciclib and ribociclib, led to practice-changing results in the setting of breast cancer. Areas covered: This review illustrates how CDK4/6-selective inhibitors got approval for the treatment of patients with either newly diagnosed or pretreated advanced hormone receptor positive, HER2-negative breast cancer. Furthermore, data about potential predictive biomarkers, as well as preclinical and preliminary clinical evidence for potential antitumor activity of CDK4/6 inhibition in other breast cancer subtypes is provided. Expert opinion: Future clinical development of CDK4/6 inhibitors in breast cancer will focus on the following aspects: i) optimization of treatment sequencing for patients with advanced disease, ii) early-stage disease, iii) other subtypes of breast cancer in rationally chosen therapeutic combinations and iv) the identification of predictive biomarkers.
科研通智能强力驱动
Strongly Powered by AbleSci AI